CG Oncology, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
CG Oncology, Inc. (CGON) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $9.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- CG Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $7.74M, a 3.63% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $1.61M, a 92.22% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $3.73M, a 11.77% increase year-over-year.
- CG Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$3.38M, a 180.39% decline year-over-year.
- CG Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $8.65M, a 58.28% increase from fiscal 2024.
- CG Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $5.47M, a 32.17% increase from fiscal 2023.
- CG Oncology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $4.14M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.35M 10-Q · filed 2026-08-06 | $13.08M derived: sum of 3 quarters · filed 2026-08-06 | $9.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.61M 10-Q · filed 2026-05-08 | $5.34M derived: sum of 2 quarters · filed 2026-05-08 | $1.96M derived: sum of 3 quarters · filed 2026-05-08 | $9.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $352.00K derived: sum of 2 quarters · filed 2026-02-27 | $7.82M derived: sum of 3 quarters · filed 2026-08-06 | $8.65M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.09M derived: sum of 2 quarters · filed 2026-08-06 | $4.92M 10-Q · filed 2025-11-14 | $8.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.30M 10-Q · filed 2026-08-06 | $11.64M derived: sum of 3 quarters · filed 2026-08-06 | $15.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $836.00K 10-Q · filed 2026-05-08 | $4.17M derived: sum of 2 quarters · filed 2026-05-08 | $8.38M derived: sum of 3 quarters · filed 2026-05-08 | $10.43M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $7.54M derived: sum of 2 quarters · filed 2026-02-27 | $9.60M derived: sum of 3 quarters · filed 2026-02-27 | $5.47M 10-K · filed 2026-02-27 |
| 2024-09-30 | $4.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.26M derived: sum of 2 quarters · filed 2025-11-14 | $2.13M 10-Q · filed 2025-11-14 | $3.89M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$2.07M 10-Q · filed 2025-08-08 | -$316.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.14M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$4.13M 10-Q · filed 2025-05-13 | -$2.37M derived: sum of 2 quarters · filed 2026-02-27 | -$916.00K derived: sum of 3 quarters · filed 2026-02-27 | |
| 2023-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.21M derived: sum of 2 quarters · filed 2026-02-27 | $4.14M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.38M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $926.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |